1. Why a Handbook Rather Than a Review

Dermal filler treatments have become one of the most frequently performed non-surgical aesthetic procedures worldwide, with hyaluronic acid (HA) fillers accounting for the majority of injectable soft-tissue augmentation because of their versatility, reversibility and favourable safety profile. Demand continues to rise, driven by patient awareness, product development and a growing emphasis on preventative and regenerative practice. The volume of procedures alone guarantees that every practitioner with a sustained caseload will meet complications.

The knowledge base is not the limiting factor. Consensus documents from the ACE Group World and the CMAC group, the American Academy of Ophthalmology's Ophthalmic Technology Assessment, and UK consensus recommendations on tissue filler-induced vision loss now provide detailed guidance. What is repeatedly missing at the point of care is operational structure: what to do first, what threshold triggers action, how much product to use, how long to persist, and when to stop treating and start referring.

This handbook therefore restates the evidence in protocol form. Each section pairs the clinical reasoning with a numbered sequence that can be followed under pressure. Where the evidence is weak, that is stated plainly rather than smoothed over — a protocol that pretends to certainty it does not have is more dangerous than an honest one.

One theme recurs throughout and deserves stating at the outset: a substantial proportion of what presents as a product complication is in fact a technique complication, and of the technique failures, inadequate post-injection moulding is the most common and the most fixable. This handbook treats massage as a clinical procedure with a defined pressure, duration and endpoint, not as a courtesy performed while the patient reaches for their coat.

2. Classification: Timing and Severity

Complications may be classified by timing of onset, by underlying pathophysiology, or by clinical severity. Timing-based classification divides events into immediate, early and delayed presentations. Immediate complications occur during treatment or within the first few hours and include pain, bruising, oedema, erythema, hypersensitivity reactions and vascular compromise. Early complications typically arise within days to weeks and include infection, herpes simplex virus reactivation, filler malposition and the Tyndall effect. Delayed complications may develop months or years after treatment and include inflammatory nodules, granuloma formation, filler migration and chronic oedema.

A severity-based classification is often more useful clinically because it separates mild aesthetic concerns requiring reassurance from vascular and ophthalmic emergencies requiring immediate intervention. In practice, the two systems are used together: timing tells you what the differential is, severity tells you how fast you must move.

The operational value of classification is triage. A patient telephoning at 48 hours with a firm, painless lump is on a different pathway from a patient telephoning at 20 minutes with pain out of proportion and a mottled cheek. The most dangerous error is to place the second patient into the first pathway — to offer review in 24 hours when the correct answer is to be seen within the hour.

3. Prevention I: Patient Selection and Consent

The most effective strategy for managing dermal filler complications is prevention, and prevention begins before a needle is opened. A comprehensive medical history should identify previous filler treatments and their outcomes, previous filler complications, autoimmune disease, immunosuppression, active infection of any site, dental infection or untreated dental disease, a history of herpes simplex reactivation, and previous hypersensitivity reactions.

Patients presenting with active bacterial, viral or fungal infection at or near the treatment site should generally defer treatment until the infection has resolved. Untreated dental disease deserves particular emphasis because it may increase the risk of delayed inflammatory complications through bacterial seeding, and should be addressed before treatment where possible. Patients with a history of perioral herpes simplex undergoing lip treatment warrant antiviral prophylaxis.

Psychological assessment is an equal component of selection. Unrealistic expectations, body dysmorphic disorder and excessive treatment-seeking behaviour are associated with dissatisfaction and poorer outcomes irrespective of technical result. A patient who cannot describe what would constitute a good outcome will not recognise one.

Informed consent is a clinical safety intervention, not paperwork. Patients should be counselled on common adverse effects — bruising, swelling, tenderness, transient discomfort — and on less frequent events including infection, delayed inflammatory reactions, vascular occlusion and tissue necrosis. Recent UK consensus guidance recommends that all patients undergoing filler treatment be informed of the rare but potentially devastating risks of blindness and stroke during the consent process. Approximately 19% of reported cases of filler-induced vision loss demonstrated concurrent cerebral infarction, which is why consent must name both.

Consent should also generate behaviour: patients must be told to report severe pain, blanching, visual disturbance or neurological symptoms immediately, and must be given a route to do so that does not depend on office hours. A patient who waits until Monday morning because nobody answered on Saturday has been failed by the consent process, not by the product.

4. Prevention II: Anatomy, Plane and Injection Technique

Detailed understanding of facial vascular anatomy remains one of the most important determinants of safe practice, because most severe complications arise from vascular injury or inadvertent intravascular injection. The extensive anastomotic network between branches of the internal and external carotid arteries explains how filler emboli may travel retrogradely and subsequently enter the ophthalmic circulation. Particular caution applies to the glabella, nose, forehead, temple and nasolabial fold. In the AAO review, the nose accounted for 40% of reported cases of filler-induced blindness, followed by the forehead at 25%, glabella at 12% and temple at 9%.

No injection technique eliminates vascular risk, but several evidence-based strategies reduce either the likelihood of intravascular placement or the severity if it occurs. Slow injection reduces pressure within the syringe and surrounding tissue, decreasing the force available to propel filler into the vascular system and reducing the likelihood of overcoming arterial systolic pressure to generate retrograde embolisation. Low extrusion pressure — gentle, controlled thumb force — reduces the volume and distance of embolisation should vascular entry occur.

Small-volume aliquots limit the amount of product deposited at any one time. If inadvertent intravascular injection occurs, a smaller embolic volume is less likely to occlude multiple arterial branches and may reduce the extent of ischaemia. Small aliquots also reduce bolus pressure, itself a key determinant of arterial entry. Continuous needle or cannula movement while injecting reduces the duration for which the tip remains in a single location, decreasing the chance of depositing a large volume directly into a vessel.

Appropriate depth selection allows injection within tissue planes where major vessels are less likely to be encountered. However, vessel depth varies considerably between regions and individuals, meaning no plane can be considered risk-free; depth must be combined with the other strategies rather than relied upon alone. Depth is also inseparable from entry angle and vector: the same entry point approached at 90 degrees and at 45 degrees, with the same 5 mm of travel, deposits product in two different anatomical layers. Practitioners should describe placement in terms of plane reached, not needle length used.

Blunt-tipped cannulas are often advocated because they may displace vessels rather than penetrate them, potentially reducing arterial cannulation in selected regions. Vascular occlusion has nonetheless been reported with both needles and cannulas, demonstrating that neither technique eliminates risk. Large boluses in high-risk areas — glabella, nose, forehead, temple — should be avoided in favour of incremental placement with repeated reassessment.

5. Prevention III: Massage as a Clinical Procedure

Massage occupies an odd position in aesthetic practice: universally recommended, almost never specified, and consequently performed badly. The instruction 'massage the area' appears in product literature, in consensus protocols and in course notes without a defined pressure, duration, hand position or endpoint. The result is that most post-injection moulding consists of a light fingertip circling for a few seconds, which achieves very little beyond making both parties feel that something has been done.

Effective moulding is firm. The tissue should visibly deform under the pressure applied. The product should be compressed between two points of contact — typically thumb and index finger for the lip, or finger against underlying bone for the cheek, chin and jawline — so that the force is transmitted through the deposit rather than sliding across the skin surface. Pressure should be sustained and directional, moving product from where it is to where it should be, and it should be repeated rather than performed once.

Duration matters as much as pressure. A realistic standard is 60 to 120 seconds of focused work per site, repeated across the treated region, and repeated again after a short interval once initial oedema has settled. Practitioners consistently underestimate how long this takes; the honest test is whether the clinician's hand tires. If it does not, the massage was probably inadequate.

The lips illustrate the point most clearly. Hyaluronic acid placed in the lip body does not automatically distribute itself into an even, continuous roll. It sits where it was left, as discrete pockets separated by untreated tissue. Under casual inspection the lip looks acceptable; under stretch, under angled light, or under a patient's own close bathroom mirror, those pockets become visible as beading along the vermilion or as an irregular contour on eversion. An experienced practitioner can identify an inadequately massaged lip across a consulting room — the give-away is a lip that looks segmented rather than continuous, with visible interruptions in the roll.

This is not a cosmetic footnote. A meaningful proportion of hyaluronidase administered in aesthetic practice is used to dissolve product that was correctly chosen, correctly placed and simply never moulded. Dissolution in that setting is a technique failure managed pharmacologically, at cost to the patient in money, time, swelling and confidence — and with the loss of a result that firm massage at the time of treatment, or at the two-week review, would have produced.

Massage is also therapeutic after the fact. Massage and local heat continue to be recommended as adjunctive measures in vascular occlusion, where massage is thought to mechanically disperse filler material and facilitate redistribution of embolic product while heat may promote cutaneous vasodilatation and increase regional blood flow. It is important to state the evidential limits honestly: no prospective or randomised study has demonstrated that massage or heat alone improves tissue survival or reduces necrosis, and contemporary guidance is explicit that these measures must never delay or replace prompt high-dose hyaluronidase. Massage is an adjunct in ischaemia and a primary tool in moulding — the two roles should not be confused.

6. Emergency Preparedness and Clinical Governance

Complication preparedness is now regarded as a core component of safe aesthetic practice. Every practitioner performing filler treatments should maintain a structured complication management protocol, such as the ACE Group World guideline, and have immediate access to the relevant emergency medications and equipment.

Traditional emergency kits focus on vascular occlusion and typically include hyaluronidase, sterile saline, aspirin and written treatment algorithms. Recent UK consensus recommendations expand preparedness to include ophthalmic emergencies. Clinics performing filler treatments should consider maintaining a dedicated vision-loss emergency kit containing timolol 0.5% eye drops, aspirin 300 mg, hyaluronidase with a minimum of 7500 IU available, written emergency protocols, a paper bag for rebreathing, and the contact details of the nearest emergency department and ophthalmology service.

Preparedness is not the presence of a box. It is the ability to reach the box, reconstitute its contents and act within minutes, at any point during a working day, by any clinician present. Kits should be checked against expiry dates on a scheduled basis, their location known to all staff, and the protocol rehearsed rather than merely filed. Practitioners should establish predefined referral pathways so that a patient with suspected visual compromise can be transferred to the nearest emergency department immediately, without a search for a telephone number.

Documentation belongs in the protocol. Photographs at presentation and at each review, times of onset and of each intervention, doses administered, and the content of conversations with the patient all matter clinically and medicolegally. In a complication that resolves, the record demonstrates competence. In one that does not, it is the only account of what actually happened.

7. Vascular Occlusion: Recognition

Vascular occlusion remains the most serious acute complication of dermal filler treatment because delayed recognition may result in tissue necrosis, permanent scarring, blindness and, rarely, cerebrovascular injury. Vascular compromise may occur through direct intra-arterial injection or through external compression of vessels by filler material and associated oedema. Intra-arterial injection is generally associated with more severe outcomes because embolic obstruction may completely interrupt distal perfusion.

Early recognition is the single most important determinant of successful treatment. The classical presentation includes immediate blanching, severe or disproportionate pain, delayed capillary refill, cool skin temperature, a reticulated livedo pattern and progressive dusky discolouration. The pattern of skin change often corresponds to the vascular territory involved and may extend considerably beyond the original injection site.

Two caveats are frequently missed. First, pain may be absent and must not be treated as a prerequisite for diagnosis; painless occlusions are described, particularly where local anaesthetic has been used. Second, the appearance may evolve over minutes to hours, so a normal-looking area immediately after injection does not exclude compromise. Any suspicion of vascular compromise should prompt immediate intervention rather than observation.

Capillary refill assessment is among the most valuable bedside tools. Gentle pressure is applied to the affected skin until blanching occurs, and the speed of colour return observed. Delayed refill suggests ongoing hypoperfusion and may indicate persistent obstruction. Repeated assessment throughout treatment provides an objective measure of response and guides decisions regarding repeat hyaluronidase administration. Comparison with an equivalent contralateral site reduces subjectivity.

8. Vascular Occlusion: The First Twenty Minutes

Once vascular compromise is suspected, the sequence matters more than any individual step. Stop injecting immediately. Assess the extent of tissue involvement. Mark and photograph the affected area so that progression or resolution can be judged objectively. Assess capillary refill. Commence hyaluronidase treatment without delay. Apply adjunctive measures. Arrange close follow-up.

The most common failure at this stage is diagnostic hesitation — waiting for the picture to declare itself before committing to treatment. Because irreversible tissue injury may occur within hours of arterial occlusion, and because hyaluronidase carries a comparatively low risk profile in this setting, the balance of harm strongly favours early treatment of a suspected occlusion over confirmed diagnosis of an established one. Treating a suspected occlusion that turns out to be bruising costs a dissolved result; failing to treat a real one costs tissue.

Explain to the patient what is happening while you work. A patient who understands that they are receiving an antidote, that this is a recognised event with an established pathway, and that they will be reviewed at defined intervals, is far more likely to comply with follow-up and far less likely to disengage. Consent for hyaluronidase — including the risk of dissolving the aesthetic result and the rare risk of hypersensitivity — should be obtained verbally and documented contemporaneously.

9. Hyaluronidase: Pharmacology, Dose and Timing

Hyaluronidase is an enzyme that hydrolyses hyaluronic acid through cleavage of glycosidic bonds within the HA polymer. It remains the only targeted pharmacological treatment capable of directly reversing HA filler-induced vascular compromise. It degrades both endogenous and exogenous HA, reducing filler volume and facilitating restoration of blood flow where obstruction is caused by HA filler. Enzymatic activity occurs rapidly, although repeat administration may be required because of the persistence of highly cross-linked products and the relatively short tissue half-life of the enzyme.

Current evidence supports the earliest possible administration when vascular compromise is suspected. Treatment should not be delayed while awaiting progression of symptoms, because irreversible injury may occur within hours. Numerous case reports demonstrate successful tissue salvage following prompt intervention, even in extensive occlusions.

The ACE Group World protocol recommends reconstituting hyalase using 1–5 ml diluent, with dilution in 2 ml bacteriostatic saline commonly used during management of vascular compromise. Initial treatment typically involves infiltration of 450–1500 IU throughout the affected tissue and along the course of the involved vessel. Massage and local heat are recommended adjunctive measures, followed by reassessment after one hour. If capillary refill remains impaired, repeat treatment may be administered at hourly intervals for up to four cycles. These recommendations align closely with CMAC and international consensus guidance advocating repeated high-dose treatment based on clinical response rather than arbitrary maximum dosing.

Two practical points deserve emphasis. First, dose should follow territory: the enzyme must be distributed along the anatomical course of the affected vessel, not concentrated at the injection point, because the embolus may have travelled. Second, the endpoint is clinical — restoration of capillary refill, colour and warmth — not a predetermined number of units. Under-dosing a large territory is a recognised cause of apparent hyaluronidase failure.

Documented allergy to hyaluronidase or to bee or wasp venom warrants caution, and resuscitation facilities should be available. In the emergency setting the risk of withholding treatment almost always exceeds the risk of administering it.

10. Adjunctive Therapies: What Helps, What Is Theatre

Adjunctive measures are commonly incorporated into the management of vascular occlusion, and it is worth separating those with a mechanistic rationale from those retained by habit.

Massage and warmth are recommended in consensus protocols. Massage may mechanically disperse embolic product and facilitate redistribution; heat may promote cutaneous vasodilatation and increase regional blood flow. Robust clinical evidence supporting their independent effectiveness is lacking, and neither should be allowed to delay hyaluronidase. When performed, massage in this setting should be firm and sustained over the ischaemic territory, following the vascular course, rather than a token rub.

Aspirin is frequently included in treatment algorithms for its antiplatelet effect and theoretical ability to reduce secondary thrombosis. Most contemporary protocols recommend 300 mg where no contraindication exists. Important contraindications include hypersensitivity to aspirin or other NSAIDs, active gastrointestinal ulceration or bleeding, bleeding disorders including haemophilia and thrombocytopenia, severe hepatic impairment, and aspirin-exacerbated respiratory disease, along with concurrent anticoagulation where bleeding risk may outweigh benefit. Caution also applies in uncontrolled hypertension and previous haemorrhagic stroke.

Nitroglycerin paste was historically advocated for its vasodilatory properties. Recent guidance no longer recommends routine use, because vasodilatation alone does not address embolic obstruction and theoretical concerns remain regarding distal embolisation. Its removal from protocols is an example of consensus following mechanism rather than tradition.

High-frequency ultrasound is increasingly incorporated into complication management, allowing visualisation of filler location, identification of vascular structures, assessment of nodules and guidance of hyaluronidase treatment. Ultrasound-guided dissolution may improve precision and reduce unnecessary degradation of correctly placed product. Availability remains uneven, and ultrasound should support rather than delay emergency treatment.

11. Ophthalmic Complications and Vision Loss

Vision loss remains the most feared complication of filler treatment because it is sudden, potentially irreversible and frequently associated with profound psychological distress for both patient and practitioner. The AAO Ophthalmic Technology Assessment reviewed 198 published cases of filler-induced vision loss and represents the largest evidence synthesis currently available: HA accounted for 83% of reported cases and autologous fat for 15%, and vision remained unchanged in approximately 70% of affected patients despite treatment. Concurrent cerebral infarction was identified in nearly one-fifth of reported cases.

Patients may present with sudden visual loss, blurred vision, visual field defects, diplopia, ocular pain or loss of colour vision. Ptosis and ophthalmoplegia are also common features. Approximately 19% of reported cases demonstrate concurrent cerebral involvement, so every patient with visual symptoms after filler must also be assessed for stroke-like features.

UK consensus guidance recommends immediate transfer to the nearest emergency department without delay. While awaiting transfer, clinicians may initiate ocular massage, timolol 0.5% eye drops, aspirin 300 mg and paper-bag rebreathing, provided these measures do not delay definitive assessment. Clinics should maintain a dedicated vision-loss kit and ideally have access to at least 7500 IU of hyaluronidase.

Evidence for retrobulbar hyaluronidase in retinal arterial occlusion is limited and should be presented honestly. A systematic review underpinning the UK consensus identified 17 published cases in which retrobulbar hyaluronidase was administered for filler-induced vision loss; only three patients (17.6%) demonstrated any improvement in visual function, while 14 (82.4%) experienced no measurable recovery. Retrobulbar hyaluronidase cannot therefore be recommended as a reliably effective treatment for filler-induced retinal ischaemia. The consensus group nonetheless concluded that periocular or retrobulbar hyaluronidase may still be considered in carefully selected patients, performed by clinicians with specific training and experience in periocular or retrobulbar injection — ophthalmologists or oculoplastic surgeons — because the procedure carries relatively low procedural risk and isolated cases of visual recovery are reported.

For the aesthetic practitioner the operational conclusion is straightforward: your role in vision loss is rapid recognition, immediate initiation of the holding measures above, and immediate transfer. Attempting a retrobulbar injection without training is not heroism; it is a second complication.

12. Delayed Inflammatory Reactions

Delayed inflammatory reactions (DIRs) are among the most diagnostically challenging filler complications because they may occur weeks, months or even years after treatment. Patients typically present with swelling, erythema, tenderness and inflammatory nodules affecting previously treated areas. The pathogenesis remains incompletely understood but is thought to involve a complex interaction between filler material, host immunity and bacterial contamination.

Triggering events may include systemic infection, dental treatment, trauma, vaccination and other forms of immune activation. The emergence of DIRs following SARS-CoV-2 infection and COVID-19 vaccination has further highlighted the immunological basis of these complications.

Management begins with differentiation between inflammatory and infective causes, which is the pivotal decision. Hyaluronidase frequently forms part of treatment because removal of the triggering HA substrate may reduce ongoing inflammation. Where infection is suspected, broad-spectrum antibiotics should be considered before corticosteroid therapy is initiated — starting steroids into an undiagnosed infection is a recognised route to a much worse problem.

Practical sequencing for a suspected DIR is: exclude infection clinically (fever, fluctuance, rapidly progressive erythema, systemic upset, purulence); if infection cannot be excluded, treat as infection first with a broad-spectrum agent covering typical skin flora; where infection is excluded or treated and inflammation persists, consider hyaluronidase to remove substrate; reserve oral corticosteroids for significant inflammatory reactions after infection has been addressed, and involve a colleague with complications experience early rather than late. High-frequency ultrasound may assist by identifying filler location and differentiating inflammatory from non-inflammatory pathology.

13. Nodules, Lumps and the Moulding Problem

Nodule formation is a recognised delayed complication of filler treatment, and the first and most important distinction is between non-inflammatory and inflammatory nodules, because their management diverges completely.

Non-inflammatory nodules are typically caused by superficial placement, product accumulation or overcorrection. Patients present with visible or palpable lumps in the absence of tenderness, erythema or swelling. Management options include observation, massage, needle disruption and targeted hyaluronidase where HA fillers are involved. The order of that list is deliberate: the least destructive effective intervention should be attempted first.

This is where the massage standard set out in Section 5 earns its place. A firm, sustained, correctly directed moulding at the two-week review will resolve a substantial proportion of early non-inflammatory irregularity — particularly in the lips, where product commonly sits as discrete pockets rather than a continuous roll. The technique is two-point compression: the deposit is trapped between thumb and index finger (or finger and bone in the midface), compressed firmly enough to deform the tissue, and worked along the intended vector for 60 to 120 seconds per site. Patients can be taught to do this at home, with explicit instruction on pressure — the common failure at home is exactly the same as in clinic, namely a stroke rather than a compression.

Where massage fails, small-volume targeted hyaluronidase is appropriate, using low doses aimed precisely at the deposit rather than the whole region. Ultrasound guidance improves precision where available. The goal is to remove the excess, not the result.

Inflammatory nodules are characterised by erythema, tenderness, swelling and induration. Differential diagnoses include delayed hypersensitivity reactions, granuloma formation and infection. Current consensus guidance recommends a staged approach involving exclusion of infection, selective use of antibiotics and consideration of hyaluronidase where appropriate. They should never be massaged aggressively or dismissed as a moulding issue.

The Tyndall effect occurs when superficially placed HA filler scatters light through overlying skin, producing a characteristic blue-grey discoloration. The tear trough is the most commonly affected region owing to its thin skin and limited soft-tissue coverage. Prevention relies on appropriate product selection, correct injection depth and conservative volumisation. Once established, hyaluronidase is the treatment of choice because it directly removes the causative material; massage will not correct a depth error.

14. Infection, Biofilm and Hypersensitivity

Infectious complications are uncommon but potentially serious. Clinical features may include pain, erythema, warmth, swelling, fluctuance and abscess formation. Most infections result from bacterial contamination during injection, although haematogenous spread from distant sites is described — which is why active infection elsewhere, including dental infection, is a reason to defer treatment.

Biofilms are structured communities of microorganisms embedded within a protective extracellular matrix and have been proposed as a mechanism underlying some delayed filler complications. Although their precise role remains debated, biofilms may explain recurrent inflammatory episodes occurring months or years after treatment. Management depends on clinical severity and may include antibiotics, drainage, microbiological investigation and hyaluronidase where indicated. Because biofilm-associated inflammation is characteristically recurrent and steroid-responsive but steroid-dependent, repeated courses of corticosteroid without microbiological consideration should raise suspicion.

True allergic reactions to modern HA fillers remain uncommon because HA is highly conserved across species and exhibits low intrinsic immunogenicity. Presentations range from mild localised swelling to diffuse oedema and, rarely, angioedema. Mild reactions may be managed conservatively with observation and antihistamines, whereas more significant reactions may require corticosteroid therapy and specialist review. Although exceedingly rare, clinicians should remain prepared to recognise and manage anaphylaxis in accordance with established emergency protocols — which means adrenaline available and in date, not merely antihistamines.

15. Aftercare, Review and the Complication That Never Happens

Structured aftercare converts a good technical result into a durable one and catches problems while they are still cheap to fix. Patients should leave with written aftercare, a description of expected findings, a clear list of red-flag symptoms — severe or increasing pain, blanching, mottling, visual disturbance, neurological symptoms, fever — and a route of contact that functions out of hours.

A two-week review should be routine rather than exceptional for filler patients. At that visit, oedema has largely resolved and product has settled, making irregularity assessable and, critically, still correctable by moulding. The lip should be examined at rest, on stretch and on eversion, in good and in angled light, because segmentation and beading are far more visible in some conditions than others. Cheek, chin and jawline deposits should be palpated against bone. Where irregularity is found, it should be moulded firmly at that appointment and the patient taught to continue at home.

Photography at baseline, at treatment and at review is not vanity. It is the objective record that allows a practitioner to distinguish a new lump from a pre-existing asymmetry, and to demonstrate progression or resolution in a complication.

The wider point is that complication management begins long before the complication. Selection, consent, anatomy, plane, pressure, aliquot size, moulding and review are all interventions against future events. The practitioner who spends an extra ninety seconds moulding each lip and an extra two minutes explaining red flags will, over a career, dissolve less product, refund less money and explain fewer bad outcomes than the one who does not.

16. Future Directions and the Standard to Aim For

The management of filler complications continues to evolve alongside imaging technology, anatomical research and emergency care pathways. High-frequency ultrasound is increasingly integrated into routine practice and may facilitate safer injection through improved visualisation of facial vasculature and filler placement, as well as more precise dissolution. Advances in digital imaging, artificial intelligence and three-dimensional facial analysis are expected to contribute to automated landmark detection, volumetric analysis, symmetry assessment and reproducible baseline documentation, and machine learning approaches integrating facial imaging with anatomical datasets have been proposed to predict high-risk injection zones — though these remain largely investigational and require clinical validation.

The publication of UK consensus guidelines for tissue filler-induced vision loss represents an important step towards standardised complication management. Future development of national referral pathways, standardised emergency kits and structured complication training programmes may further improve outcomes.

None of that changes the standard an individual practitioner should hold today. Every injector should be able to state, without notes: the first five actions on suspecting a vascular occlusion; where the hyaluronidase is, how much of it there is, and how it is reconstituted; the contents and location of the vision-loss kit; the referral route for visual compromise, by name and number; and the difference in management between an inflammatory and a non-inflammatory nodule. Anyone who cannot is not yet ready to be injecting the glabella, the nose or the tear trough.

Dermal fillers remain among the safest and most versatile tools in medical aesthetics when administered by appropriately trained clinicians. The increasing recognition of vascular, ophthalmic and neurological complications does not undermine that; it defines the standard of preparation the work requires. Prevention remains the most effective strategy, and it begins with careful patient selection, detailed anatomical knowledge, informed consent that names the worst outcomes, meticulous injection technique — and moulding performed as a procedure rather than a gesture.